First Wave

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Following its 2024 merger with ImmunogenX, the company's lead asset is Latiglutenase, a Phase 3-ready oral enzyme therapy designed to degrade gluten for the treatment of celiac disease. The pipeline also features Adrulipase, a recombinant lipase for exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis, and Caplosan, an oral niclosamide formulation for ulcerative proctitis. By focusing on gut-restricted mechanisms, First Wave BioPharma aims to provide effective treatments while avoiding the complications associated with systemic drug absorption. The company is headquartered in Boca Raton, Florida, and is publicly traded on the NASDAQ exchange.